Cited by 377Parkinson's Disease Mechanisms and TreatmentsStatistical Methods in EpidemiologyDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Risk tables for parkinsonism and Parkinson’s disease

Elbaz, Alexis, Bower, James H, Maraganore, Demetrius M, McDonnell, Shannon K, Peterson, Brett J, Ahlskog, J.Eric, Schaid, Daniel J, Rocca, Walter A·2002·Journal of Clinical Epidemiology

DOI 10.1016/s0895-4356(01)00425-5

Open this paper in CoChat — free account

Abstract

We applied the incidence rates of parkinsonism and Parkinson's disease (PD) from Olmsted County, MN (1976-1990) to a hypothetical cohort undergoing the mortality rates observed in Minnesota, and computed the lifetime risk and the remaining lifetime risk of developing parkinsonism and PD. These risks were compared to cumulative incidences that do not take competing risks of death into account. The lifetime risk of developing parkinsonism from birth was 4.4% for men and 3.7% for women (ratio = 1.2). The corresponding risk of developing PD was 2.0% for men and 1.3% for women (ratio = 1.5). Because of the opposite effect of higher incidence and higher mortality rates in men, the lifetime risks were only slightly higher in men than in women. Lifetime cumulative incidences were consistently higher than lifetime risks; this difference was more pronounced in men and in older subjects. Lifetime risk estimates are useful in clinical practice, epidemiologic research, and public health.

Integrity signals

Registry

Crossref · 10.1016/s0895-4356(01)00425-5

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease.
de Rijk, M. C., Tzourio, C., Breteler, M. M., Dartigues, J. F., Amaducci, L., Lopez-Pousa, S., Manubens-Bertran, J. M., Alperovitch, A., & Rocca, W. A. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.1.10 · Cited by 833
The Patient Record in Epidemiology
Kurland, L. T., & Molgaard, C. A. (1981) · Scientific American · doi:10.1038/scientificamerican1081-54 · Cited by 780
The Lifetime Risk of Developing Breast Cancer
Feuer, E. J., Wun, L., Boring, C. C., Flanders, W. D., Timmel, M. J., & Tong, T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.11.892 · Cited by 640
Parkinson’s disease and parkinsonism in a longitudinal study: Two-fold higher incidence in men
Baldereschi, M., Di Carlo, A., Rocca, W. A., Vanni, P., Maggi, S., Perissinotto, E., Grigoletto, F., Amaducci, L., & Inzitari, D. (2000) · Neurology · doi:10.1212/wnl.55.9.1358 · Cited by 526
Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990
Bower, J. H., Maraganore, D. M., McDonnell, S. K., & Rocca, W. A. (1999) · Neurology · doi:10.1212/wnl.52.6.1214 · Cited by 509
Lifetime risk of dementia and Alzheimer's disease: The impact of mortality on risk estimates in the Framingham Study
Seshadri, S., Wolf, P. A., Beiser, A., Au, R., McNulty, K., White, R., & D'Agostino, R. B. (1997) · Neurology · doi:10.1212/wnl.49.6.1498 · Cited by 489
Incidence and Risk of Dementia: The Rotterdam study
Ott, A., Breteler, M. M. B., Harskamp, F. V., Stijnen, T., & Hofman, A. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009489 · Cited by 455
The Frequency of Idiopathic Parkinson's Disease by Age, Ethnic Group, and Sex in Northern Manhattan, 1988–1993
Mayeux, R. P., Marder, K. S., COTE, L. J., Denaro, J. E., Hemenegildo, N., Mejia‐Santana, H., Tang, M., Lantigua, R., Wilder, D., Gurland, B. J., et al. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117721 · Cited by 387
Risk of Parkinson's disease among first-degree relatives
Marder, K. S., Tang, M., Mejía, H., Alfaro, B., Cote, L. J., Louis, E. K. S., Groves, J. T., & Mayeux, R. P. (1996) · Neurology · doi:10.1212/wnl.47.1.155 · Cited by 248

Show all 21 references

Sorted by citations

The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,930
MDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,394
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Description of Parkinson's Disease as a Clinical Syndrome
Fahn, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 979
Accurate Telemonitoring of Parkinson's Disease Progression by Noninvasive Speech TestsPreprint
Tsanas, A., Little, M. A., McSharry, P., & Ramig, L. O. (2009) · Nature Precedings · doi:10.1109/tbme.2009.2036000 · Cited by 833
Considering sex and gender in Alzheimer disease and other dementias
Podcasy, J., & Epperson, C. N. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.4/cepperson · Cited by 727
Diagnosis and treatment of Parkinson disease: molecules to medicine
Savitt, J. M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29178 · Cited by 660
E PIDEMIOLOGY OF N EURODEGENERATION
Mayeux, R. P. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.043002.094919 · Cited by 531
Neurodegenerative Diseases: An Overview of Environmental Risk Factors
Brown, R. C., Lockwood, A. H., & Sonawane, B. R. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7567 · Cited by 538
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse
Itier, J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg239 · Cited by 523
High-Resolution Whole-Genome Association Study of Parkinson Disease
Maraganore, D. M., de Andrade, M., Lesnick, T. G., Strain, K. J., Farrer, M. J., Rocca, W. A., Pant, P. V. K., Frazer, K. A., Cox, D., & Ballinger, D. G. (2005) · The American Journal of Human Genetics · doi:10.1086/496902 · Cited by 505
Sex differences in Parkinson’s disease
Gillies, G. E., Pienaar, I. S., Vohra, S., & Qamhawi, Z. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.02.002 · Cited by 521
Epidemiology of Parkinson's disease
Elbaz, A., Carcaillon‐Bentata, L., Kab, S., & Moisan, F. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.09.012 · Cited by 487
Sex differences in neurodevelopmental and neurodegenerative disorders: Focus on microglial function and neuroinflammation during development
Hanamsagar, R., & Bilbo, S. D. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.09.039 · Cited by 404
Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study
Seshadri, S. S., & Wolf, P. A. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70291-0 · Cited by 367
Nonlinear speech analysis algorithms mapped to a standard metric achieve clinically useful quantification of average Parkinson's disease symptom severity
Tsanas, A., Little, M. A., McSharry, P., & Ramig, L. O. (2010) · Journal of The Royal Society Interface · doi:10.1098/rsif.2010.0456 · Cited by 323
Neurodegenerative Diseases and Exposure to Pesticides in the Elderly
Baldi, I. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwf216 · Cited by 320
The neuropathology of genetic Parkinson's disease
Poulopoulos, M., Levy, O. A., & Alcalay, R. N. (2012) · Movement Disorders · doi:10.1002/mds.24962 · Cited by 315
Incidence and remaining lifetime risk of Parkinson disease in advanced age
Driver, J. A., Logroscino, G., Gaziano, J. M., & Kurth, T. (2009) · Neurology · doi:10.1212/01.wnl.0000341769.50075.bb · Cited by 298
Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease
Gan-Or, Z., Dion, P. A., & Rouleau, G. A. (2015) · Autophagy · doi:10.1080/15548627.2015.1067364 · Cited by 260
A compensatory role for declarative memory in neurodevelopmental disorders
Ullman, M. T., & Pullman, M. Y. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.008 · Cited by 263
Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study
Benito‐León, J., Louis, E. D., Bermejo‐Pareja, F., & on behalf of the Neurological Disorders in Central Spain (NEDICES) Study Group (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.147223 · Cited by 237
The diagnosis of manganese-induced parkinsonism
Cersosimo, M. G., & Koller, W. C. (2005) · NeuroToxicology · doi:10.1016/j.neuro.2005.10.006 · Cited by 234
Levodopa in the treatment of Parkinson's disease
Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02697.x · Cited by 231
A new hybrid intelligent system for accurate detection of Parkinson's disease
Hariharan, M., Polat, K., & Sindhu, R. (2014) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2014.01.004 · Cited by 223
Gender differences in Parkinson’s disease: A clinical perspective
Georgiev, D., Hamberg, K., Hariz, M., Forsgren, L., & Hariz, G.-M. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12796 · Cited by 220
G2019S LRRK2 mutation in French and North African families with Parkinson's disease
Lesage, S., Ibáñez, P., Lohmann, E., Pollak, P., Tison, F., Tazir, M., Leutenegger, A., Guimaraes, J., Bonnet, A., Agid, Y., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20636 · Cited by 217
Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism
Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., & Rocca, W. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.114 · Cited by 196
Musically Cued Gait-Training Improves Both Perceptual and Motor Timing in Parkinson’s Disease
Benoit, C.-É., Bella, S. D., Farrugia, N., Obrig, H., Mainka, S., & Kotz, S. A. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00494 · Cited by 194
Modelling of Parkinson's disease in mice
Chesselet, M., & Richter, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70227-7 · Cited by 190
Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease
Huang, X., Chen, H., Miller, W. C., Mailman, R. B., Woodard, J. L., Chen, P., Xiang, D., Murrow, R. W., Wang, Y., & Poole, C. (2006) · Movement Disorders · doi:10.1002/mds.21290 · Cited by 190
Gait improvement via rhythmic stimulation in Parkinson’s disease is linked to rhythmic skills
Bella, S. D., Benoit, C.-É., Farrugia, N., Keller, P. E., Obrig, H., Mainka, S., & Kotz, S. A. (2017) · Scientific Reports · doi:10.1038/srep42005 · Cited by 187
HDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 188
Neuroprotective Herbs and Foods from Different Traditional Medicines and Diets
Iriti, M., Vitalini, S., Fico, G., & Faoro, F. (2010) · Molecules · doi:10.3390/molecules15053517 · Cited by 191
High prevalence of parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries
Lucchini, R. G., Albini, E., Benedetti, L., Borghesi, S., Coccaglio, R., Malara, E. C., Parrinello, G., Garattini, S., Resola, S., & Alessio, L. (2007) · American Journal of Industrial Medicine · doi:10.1002/ajim.20494 · Cited by 179
Parkinson’s Disease Psychosis: Presentation, Diagnosis and Management
Schneider, R. B., Iourinets, J., & Richard, I. H. (2017) · Neurodegenerative Disease Management · doi:10.2217/nmt-2017-0028 · Cited by 180
Searching for a relationship between manganese and welding and Parkinson’s disease
Jankovic, J. J. (2005) · Neurology · doi:10.1212/01.wnl.0000166916.40902.63 · Cited by 175
Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?
Frigerio, R., Fujishiro, H., Ahn, T. B., Josephs, K. A., Maraganore, D. M., DelleDonne, A., Parisi, J. E., Klos, K. J., Boeve, B. F., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.019 · Cited by 172
Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics
Lin, L., Lesnick, T. G., Maraganore, D. M., & Ole Isacson, A. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.11.006 · Cited by 165
LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same
Berwick, D. C., Heaton, G. R., Azeggagh, S., & Harvey, K. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0344-2 · Cited by 181
Risk of Parkinson disease in women
Ragonese, P., D’Amelio, M., Salemi, G., Aridon, P., Gammino, M., Epifanio, A., Morgante, F., & Savettieri, G. (2004) · Neurology · doi:10.1212/wnl.62.11.2010 · Cited by 158
Racial differences in the diagnosis of Parkinson's disease
Dahodwala, N. A., Siderowf, A. D., Xie, M., Noll, E. L., Stern, M., & Mandell, D. S. (2009) · Movement Disorders · doi:10.1002/mds.22557 · Cited by 150
Genetic risk of Parkinson disease and progression:
Iwaki, H., Blauwendraat, C., Leonard, H. L., Liu, G., Maple‐Grødem, J., Corvol, J., Pihlstrøm, L., van Nimwegen, M., Hutten, S. J., Nguyen, K.-D. H., et al. (2019) · Neurology Genetics · doi:10.1212/nxg.0000000000000348 · Cited by 150
Parkinson’s Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation
Dutta, S., Verma, S., Jain, V., Surapaneni, B. K., Vinayek, R., Phillips, L. E., & Nair, P. P. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19044 · Cited by 150
Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes
Vlaar, A. M. M., van Kroonenburgh, M. J. P. G., Kessels, A. G. H., & Weber, W. E. J. (2007) · BMC Neurology · doi:10.1186/1471-2377-7-27 · Cited by 139
Epidemiologic studies of environmental exposures in Parkinson's disease
Elbaz, A., & Tranchant, C. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.06.024 · Cited by 141
Sexual differentiation of microglia
Villa, A. M., Torre, S. D., & Maggi, A. C. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.11.003 · Cited by 135
Widespread sex dimorphism in aging and age-related diseases
Sampathkumar, N. K., Bravo, J. I., Chen, Y., Danthi, P. S., Donahue, E. K., Lai, R. W., Lu, R. J., Randall, L. T., Vinson, N. M., & Benayoun, B. A. (2019) · Human Genetics · doi:10.1007/s00439-019-02082-w · Cited by 130
Comorbid conditions associated with Parkinson's disease: A population‐based study
Leibson, C. L., Maraganore, D. M., Bower, J. H., Ransom, J. E., O’Brien, P. C., & Rocca, W. A. (2005) · Movement Disorders · doi:10.1002/mds.20685 · Cited by 128
Diagnosing Parkinson by using artificial neural networks and support vector machines
Gil, D., & Johnsson, M. (2009) · Lund University Publications (Lund University) · Cited by 127
Classification of GBA1 Variants in Parkinson's Disease: The GBA1 ‐PD Browser
Parlar, S. C., Grenn, F. P., Kim, J. J., Blauwendraat, C., & Gan‐Or, Z. (2023) · Movement Disorders · doi:10.1002/mds.29314 · Cited by 131
A novel diagnosis system for Parkinson’s disease using complex-valued artificial neural network with k-means clustering feature weighting method
Gürüler, H. (2016) · Neural Computing and Applications · doi:10.1007/s00521-015-2142-2 · Cited by 121
Classification of Parkinson's disease using feature weighting method on the basis of fuzzy C-means clustering
Polat, K. (2011) · International Journal of Systems Science · doi:10.1080/00207721.2011.581395 · Cited by 120
Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010‐2030) in France
Wanneveich, M., Moisan, F., Jacqmin‐Gadda, H., Elbaz, A., & Joly, P. (2018) · Movement Disorders · doi:10.1002/mds.27447 · Cited by 117
Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long‐Standing Model
Leão, A. H. F. F., Sarmento‐Silva, A. J., dos Santos, J. R., Ribeiro, A. M., & Silva, R. H. (2015) · Brain Pathology · doi:10.1111/bpa.12253 · Cited by 132
Computer‐Aided Diagnosis of Parkinson’s Disease Using Complex‐Valued Neural Networks and mRMR Feature Selection Algorithm
Peker, M., Şen, B., & Delen, D. (2015) · Journal of Healthcare Engineering · doi:10.1260/2040-2295.6.3.281 · Cited by 115
Concordance for Parkinson's disease in twins: A 20‐year update
Goldman, S. M., MAREK, K. L., Ottman, R., Meng, C., Comyns, K., Chan, P., Ma, J., Marras, C., Langston, J. W., Ross, G. W., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25441 · Cited by 119
Sex-related differences in oxidative stress and neurodegeneration
Tenkorang, M. A. A., Snyder, B., & Cunningham, R. L. (2017) · Steroids · doi:10.1016/j.steroids.2017.12.010 · Cited by 118
Advancing the science of developmental neurotoxicity (DNT): testing for better safety evaluation
Bal‐Price, A. (2012) · ALTEX · doi:10.14573/altex.2012.2.202 · Cited by 113
Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human
Jee, H. J., Lee, S. G., Bormate, K. J., & Jung, Y.-S. (2020) · Nutrients · doi:10.3390/nu12103080 · Cited by 111
“In the Framingham Study cohort, a study conducted in individuals aged between 65 and 100 years old, incidence of AD in women was twice as high as men [41], and another study reported that two-thirds of AD patients are women [42].”
BackgroundMethod
Heritability of Parkinson disease in Swedish twins: a longitudinal study
Wirdefeldt, K., Gatz, M., Reynolds, C. A., Prescott, C. A., & Pedersen, N. L. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.017 · Cited by 113
Parkinson’s Disease and Melanoma: Co-Occurrence and Mechanisms
Bose, A., Petsko, G. A., & Eliezer, D. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-171263 · Cited by 113
A Blood-Brain Barrier (BBB) Disrupter Is Also a Potent α-Synuclein (α-syn) Aggregation Inhibitor
Shaltiel‐Karyo, R., Frenkel‐Pinter, M., Rockenstein, E. M., Patrick, C., Levy‐Sakin, M., Schiller, A., Egoz-Matia, N., Masliah, E., Segal, D., & Gazit, E. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434787 · Cited by 110
Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease
Miller, R. M., Kiser, G. L., Kaysser-Kranich, T., Lockner, R., Palaniappan, C., & Federoff, H. J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.07.010 · Cited by 110
Estrogen as Neuroprotectant of Nigrostriatal Dopaminergic System: Laboratory and Clinical Studies
Dluzen, D. E., & Horstink, M. W. I. M. (2003) · Endocrine · doi:10.1385/endo:21:1:67 · Cited by 106
A decision support system to improve medical diagnosis using a combination of k-medoids clustering based attribute weighting and SVM
Peker, M. (2016) · Journal of Medical Systems · doi:10.1007/s10916-016-0477-6 · Cited by 104
Alterations of Myelin Content in Parkinson’s Disease: A Cross-Sectional Neuroimaging Study
Dean, D., Sojkova, J., Hurley, S. A., Kecskemeti, S., Okonkwo, O. C., Bendlin, B. B., Theisen, F., Johnson, S. C., Alexander, A. L., & Gallagher, C. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163774 · Cited by 103
Sex-Related Abnormalities in Substantia Nigra Lipids in Parkinson’s Disease
Seyfried, T. N., Choi, H. S., Chevalier, A. C., Hogan, D. V., Akgoc, Z., & Schneider, J. S. (2018) · ASN NEURO · doi:10.1177/1759091418781889 · Cited by 102
Genetics of iron regulation and the possible role of iron in Parkinson's disease
Rhodes, S. L., & Ritz, B. R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.07.001 · Cited by 103
Diabetes mellitus and progression of rigidity and gait disturbance in older persons
Arvanitakis, Z., Wilson, R. S., Schneider, J. A., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Neurology · doi:10.1212/01.wnl.0000138432.16676.4b · Cited by 97
Levodopa in the treatment of Parkinson’s disease
Fahn, S. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_1 · Cited by 94
Sex effects on brain structure in de novo Parkinson’s disease: a multimodal neuroimaging study
Tremblay, C., Abbasi, N., Zeighami, Y., Yau, Y. H. C., Dadar, M., Rahayel, S., & Dagher, A. (2020) · Brain · doi:10.1093/brain/awaa234 · Cited by 91
Accurate telemonitoring of Parkinson’s disease symptom severity using nonlinear speech signal processing and statistical machine learning
Tsanas, A. (2012) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-w4ky0ynwe · Cited by 92
Neuroprotective Effects of Vanillyl Alcohol in Gastrodia elata Blume Through Suppression of Oxidative Stress and Anti-Apoptotic Activity in Toxin-Induced Dopaminergic MN9D Cells
Kim, I. S., Choi, D., & Jung, H. J. (2011) · Molecules · doi:10.3390/molecules16075349 · Cited by 91
Parkinson Disease
Zesiewicz, T. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000764 · Cited by 86
Interaction between genes and environment in neurodegenerative diseases
Elbaz, A., Dufouil, C., & Alpérovitch, A. (2007) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2007.02.018 · Cited by 85
Enhanced classical dysphonia measures and sparse regression for telemonitoring of Parkinson's disease progression
Tsanas, A., Little, M. A., McSharry, P., & Ramig, L. O. (2010) · IEEE International Conference on Acoustics Speech and Signal Processing · doi:10.1109/icassp.2010.5495554 · Cited by 85
Parkinson's disease in women: A call for improved clinical studies and for comparative effectiveness research
Pavon, J. M., Whitson, H. E., & Okun, M. S. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.01.001 · Cited by 84
Parkinson's disease in women: Mechanisms underlying sex differences
Vaidya, B., Dhamija, K., Guru, P., & Sharma, S. S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173862 · Cited by 88
Lifetime risk of common neurological diseases in the elderly population
Licher, S., Darweesh, S. K. L., Wolters, F. J., Fani, L., Heshmatollah, A., Mutlu, Ü., Koudstaal, P. J., Heeringa, J., Leening, M. J. G., Ikram, M. K., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318650 · Cited by 83
The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow
Göker-Alpan, Ö., Masdeu, J. C., Kohn, P. D., Ianni, A. M., Lopez, G. J., Groden, C. A., Chapman, M. C., Cropp, B., Eisenberg, D. P., Maniwang, E., et al. (2012) · Brain · doi:10.1093/brain/aws174 · Cited by 85
High rates and the risk factors for emergency room visits and hospitalization in Parkinson's disease
Hassan, A., Wu, S. S., Schmidt, P. N., Dai, Y. E., Simuni, T., Giladi, N., Bloem, B. R., Malaty, I. A., & Okun, M. S. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.06.006 · Cited by 82
Methamphetamine use and future risk for Parkinson’s disease: Evidence and clinical implications
Lappin, J., Darke, S. G., & Farrell, M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.02.032 · Cited by 80
Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models
Choi, J. G., Kim, H. G., Kim, M. C., Yang, W. M., Huh, Y., Kim, S. Y., & Oh, M. S. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.12.030 · Cited by 80
X chromosome number causes sex differences in gene expression in adult mouse striatum
Chen, X., Grisham, W., & Arnold, A. P. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06610.x · Cited by 79
Association of Age-Related Macular Degeneration on Alzheimer or Parkinson Disease: A Retrospective Cohort Study
Choi, S., Jahng, W. J., Park, S. M., & Jee, D. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2019.11.001 · Cited by 76
Evaluation of train and test performance of machine learning algorithms and Parkinson diagnosis with statistical measurements
Avuçlu, E., & Elen, A. (2020) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-020-02260-3 · Cited by 74
Genetic adverse selection: Evidence from long-term care insurance and Huntington disease
Oster, E. F., Shoulson, I., Quaid, K. A., & Dorsey, E. R. (2010) · Journal of Public Economics · doi:10.1016/j.jpubeco.2010.06.009 · Cited by 74
Double‐blind, placebo‐controlled study of HGF gene therapy in diabetic neuropathy
Kessler, J. A., Smith, A. G., Cha, B., Choi, S. H., Wymer, J., Shaibani, A. I., Ajroud‐Driss, S., Vinik, A. I., & VM202 DPN‐II Study Group (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.186 · Cited by 72
Parkinson’s Disease and Cognitive Impairment
Yang, Y., Tang, B., & Guo, J. (2016) · Parkinson s Disease · doi:10.1155/2016/6734678 · Cited by 79
Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era
Bassett, A. S., & Costain, G. (2012) · The Application of Clinical Genetics · doi:10.2147/tacg.s21953 · Cited by 71
Technologies for Assessment of Motor Disorders in Parkinson’s Disease: A Review
Oung, Q. W., Muthusamy, H., Lee, H. L., Basah, S. N., Yaacob, S., Sarillee, M., & Lee, C. K. (2015) · Sensors · doi:10.3390/s150921710 · Cited by 70
Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues
Menozzi, E., Toffoli, M., & Schapira, A. H. V. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108419 · Cited by 69
New machine-learning algorithms for prediction of Parkinson's disease
Mandal, I., & Sairam, N. (2012) · International Journal of Systems Science · doi:10.1080/00207721.2012.724114 · Cited by 68
Androgen Therapy in Neurodegenerative Diseases
Bianchi, V. E., Rizzi, L., Bresciani, E., Omeljaniuk, R. J., & Torsello, A. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa120 · Cited by 69
Association Between the Ubiquitin Carboxyl-Terminal Esterase L1 Gene (UCHL1) S18Y Variant and Parkinson's Disease: A HuGE Review and Meta-Analysis
Ragland, M. F., Hutter, C., Zabetian, C. P., & Edwards, K. L. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp288 · Cited by 64
Menopause and Parkinson’s disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration
Labandeira-García, J. L., Rodriguez-Perez, A. I., Valenzuela, R., Costa-Besada, M. A., & Guerra, M. J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.09.003 · Cited by 63
Peripheral Lymphocyte Subsets as a Marker of Parkinson’s Disease in a Chinese Population
Cen, L., Yang, C., Huang, S., Zhou, M., Tang, X., Li, K., Guo, W., Wu, Z., Mo, M., Xiao, Y., et al. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0163-9 · Cited by 64
What and How Can Physical Activity Prevention Function on Parkinson’s Disease?
Fan, B., Jabeen, R., Bo, B., Guo, C., Meng-jie, H., Zhang, H., Cen, J., Ji, X., & Wei, J. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4293071 · Cited by 66
Synergistic effects of influenza and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can be eliminated by the use of influenza therapeutics: experimental evidence for the multi-hit hypothesis
Sadasivan, S., Sharp, B., Schultz‐Cherry, S., & Smeyne, R. J. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0019-z · Cited by 63

Authors: Elbaz, A., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A.
Affiliations: Mayo Clinic (US)
Corresponding author: Rocca, Walter A
ORCID: Elbaz, Alexis
Bower, James H
Maraganore, Demetrius M
McDonnell, Shannon K
Ahlskog, J.Eric
Schaid, Daniel J
Rocca, Walter A
Venue: Journal of Clinical Epidemiology
Publisher: Elsevier BV
Published: 2002-01
Volume: 55
Issue: 1
Pages: 25-31
ISSN: 0895-4356 (ISSN-L)
DOI: 10.1016/s0895-4356(01)00425-5
OpenAlex: W2013713870
Cited by: 377
References: 21
Citations by year: 2026: 6 · 2025: 15 · 2024: 21 · 2023: 14 · 2022: 20 · 2021: 16 · 2020: 21 · 2019: 25 · 2018: 32 · 2017: 18 · 2016: 23 · 2015: 19 · 2014: 21 · 2013: 10 · 2012: 12
FWCI: 5.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Clinical Epidemiology (publishedVersion)
PubMed (publishedVersion)
Funders: Institut National de la Santé et de la Recherche Médicale
National Institutes of Health
National Institute of Neurological Disorders and Stroke (R01NS033978, NS33978)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR030582, AR30582)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, parkinsonism, lifetime risk, cumulative incidence, competing risk of death, incidence rates, mortality rates, sex differences, Olmsted County, Minnesota
MeSH terms: Adult, Aged, Female, Humans, Male, Middle Aged, Minnesota, Parkinson Disease, Risk Factors, Life Tables, Incidence, Age Distribution, Sex Distribution, Parkinsonian Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk tables for parkinsonism and Parkinson’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks